Today's Top 5
5. Crowdfunding for Cancer Care
Cancer is physically, mentally, and FINANCIALLY draining to the patients & their caregivers Use of an Online Crowdfunding Platform for Unmet Financial Obligations in Cancer Care https://t.co/BYwwxnzR2z
— Vivek Subbiah, MD (@VivekSubbiah) December 10, 2019
4. One or Two Checkpoint Inhibitors?
One or Two Immune Checkpoint Inhibitors? Question is valid for both melanoma and NSCLC. Different perspectives (ipi dose, duration of treatment, biomarkers, relevance of the control arm...), no definitive answer. https://t.co/o4LDNq8cKx
— Benjamin Besse (@BenjaminBesseMD) December 10, 2019
3. Trastuzumab for HER2+ Breast Cancer
Trastuzumab deruxtecan produced responses in 60% of women with HER2+ breast cancer who had received a median of six prior types of therapy. The agent is associated with myelotoxicity and gastrointestinal toxicity. #SABCS19 https://t.co/qgzydwHsMX
— NEJM (@NEJM) December 11, 2019
2. Story of a Ewing Sarcoma Survivor
After experiencing two relapses in three years, Maddie Carlson entered into an #immunotherapy clinical trial at Dana-Farber/Boston Children’s to treat her Ewing sarcoma. Today, she is disease-free. https://t.co/aefMVV1pim
— Dana-Farber (@DanaFarber) December 13, 2019
1. Understanding Cancer Evolution
Cancers don’t appear overnight. Researchers at MSK and @UBC have developed atool for sequencing the genomes of individual cancer cells on a massive scale. The resource will speed scientists’ understanding of tumor evolution. https://t.co/fOIT6SAzzn
— MemorialSloan Kettering Cancer Center (@sloan_kettering) December 13, 2019